Background. There has been no systematic evaluation of outcome after surgery for infective endocarditis with respect to duration of antibiotic treatment.
Most cases of endocarditis can be successfully managed by following well-known treatment guidelines [1, 2] . Locally, a minority of patients (17%-25%) require valve surgery as part of their endocarditis management [3, 4] . After valve replacement for active bacterial endocarditis, there is no consensus on how long to continue antimicrobial treatment. In 1982, Dinubile [5] summarized the situation by stating, "The postoperative duration of antibiotics is controversial and has not been standardized" (p. 651). The same can be said in 2005. Although some authors give consideration to either surgical findings or the results of culture, Gram stain, or histological examination [6] [7] [8] [9] [10] [11] , others continue treatment for a standard period after valve replacement [12] [13] [14] [15] [16] [17] [18] [19] [20] . The authors of 2 recent reviews [21, 22] conservatively recommend that antibiotic treatment be continued for 4-6 weeks after surgery for endocarditis.
No previous study has systematically examined bacteriological outcome of surgery for endocarditis with respect to the duration of antibiotic treatment after surgery. We have conducted a retrospective chart review to determine the frequency of relapsing infection and whether surgical findings, valve culture results, or duration of antibiotic treatment were associated with relapse.
PATIENTS AND METHODS

Patient population.
Charts were reviewed for all patients undergoing valve replacement surgery at Green Lane Hospital (Auckland, New Zealand) from September 1963 through December 1999 for bacterial or blood culture-negative endocarditis [23] . Patients with definite or possible endocarditis, as defined by the modified Duke criteria [23, 24] , were included in the study if they underwent an operation during active endocarditis (i.e., while receiving antibiotic treatment) or if incubating endocarditis was discovered at surgery [23] . Patients with cases of fungal endocarditis were excluded. All relevant clinical details were recorded in a database, including the infecting organism, duration of antibiotic treatment before and after valve surgery, and surgical findings (i.e., whether the infection was limited to valve leaflets or extended into the valve ring or whether there was involvement of the sewing ring of a prosthetic valve).
Definitions. The modified Duke criteria were used to define endocarditis, with the additional criterion of a positive microbiology Gram stain being taken as pathological evidence of definite endocarditis [23, 24] . Valve culture results were considered to be positive if the isolate recovered matched the original blood culture isolate or, if blood culture results were negative, a compatible isolate was recovered. As described elsewhere [23] , obvious plate or broth contaminants were ignored.
A patient's first episode of endocarditis was defined as the initial episode. Subsequent episodes were referred to as repeat episodes. Relapse was defined as endocarditis due to the same bacterial species occurring within 1 year after surgery and following apparently successful completion of postoperative antibiotic treatment. Relapse, therefore, represents treatment failure occurring after an apparent initial treatment success.
Surgical methods. Early surgical intervention was undertaken in patients with severe valvular insufficiency, with or without cardiac failure, multiple emboli, large vegetations, perivalvular abscess, or uncontrolled infection despite appropriate antibiotic therapy. There was a bias for early operation for those with Staphylococcus aureus or prosthetic valve endocarditis.
At surgery, a vigorous attempt was made to remove all infected tissue and foreign material. Allografts were usually used for aortic valve replacement, with use of the root replacement technique in patients with extravalvular infection.
Treatment regimens. Patients received standard intravenous doses of antibiotics in accordance with isolate drug-susceptibility results (e.g., flucloxacillin, 2 g q4h; vancomycin, 1 g q12h; gentamicin, 1 mg/kg q8h), with appropriate adjustments for impaired renal function.
Patient follow-up. Patients were followed-up either by reviewing their outpatient records or by contacting either their current general practitioner or cardiologist at the referring hospital. When no further data could be collected in this way, for patients with !2 years of follow-up information, we searched the New Zealand national data base (which records all hospitalpatient encounters and notified deaths) by each patient's unique National Hospital Information number. For hospital admissions, the main diagnosis is recorded. Treatment duration. Since 1994, we have made a conscious effort to reduce the duration of antibiotic treatment for patients with negative culture results, regardless of the type of valve or extent of intracardiac infection. We therefore analyzed the duration of treatment during 1963-1993 and 1994-1999 to see whether there was any evidence of a poorer outcome after this decision.
Statistical analysis. Results are reported as median (range) or count (percentage) unless otherwise stated. Differences in proportions were compared using Fisher's exact test and the Mann-Whitney U test was used for continuous variables. All analysis was performed using SAS statistical software (SAS), and a P value !.05 was considered to be statistically significant.
RESULTS
Patients.
Four hundred nineteen patients underwent surgery for endocarditis and met the Duke criteria for definite or pos- (3) Other gram-positive organisms b 13 (4) HACEK group 13 (4) Other gram-negative organisms c 12 (3) Cases with negative culture results 33 (9) Gram-positive cocci present 23 (6) Acute inflammation in histopathological specimen 5 Definite endocarditis by clinical criteria 1
Possible endocarditis by clinical criteria 4 NOTE. One patient had polymicrobial endocarditis with S. epidermidis and a b-haemolytic Streptococcus species recovered from multiple preoperative blood cultures. Cases of incubating endocarditis with positive valve culture results and blood culture-negative episodes with positive valve culture results are included with the respective organism. HACEK, Haemophilus (6 episodes), Actinobacillus (1), Cardiobacterium (1), Eikenella (1), and Kingella (4) Bacteriological outcome. Thirty-two patients (9%) had 36 episodes of repeat endocarditis, with 4 patients having 2 further episodes. Thirty-three of the repeat episodes were not due to relapse: 19 were due to a different species, 6 occurred 11 year after initial surgery (median duration, 5 years and 8 months; range, 1 year and 3 months to 17 years and 3 months), 5 occurred after intervening valve replacement for valve failure, and 3 occurred before the end of the initial antibiotic treatment (all 3 had negative culture results). Three (0.8%) of the patients (95% CI, 0.2%-2%) experienced relapse of their endocarditis after completing the initial antibiotic treatment (table 3) . Regrettably, in each case, 1 or both isolates were unavailable, preventing molecular analysis of isolate relatedness.
Relapse. Relapse was as frequent in those patients treated for 13 weeks as it was in those receiving р3 weeks of treatment after surgery (2 of 236 vs. 1 of 122;
) ( with prosthetic valve infection (4 of these with invasion). The organisms involved were streptococci (26 isolates), staphylococci (10 isolates, 7 of which were S. aureus), other grampositive cocci (4 isolates), Corynebacterium species (2 isolates), and gram-negative bacilli (3 isolates). Nine patients had culture-negative infection, but all 9 of these patients had definite endocarditis according to Duke pathological criteria. The median duration of treatment before surgery was 17 days (range, 2-53 days), and the median total duration of treatment was 29 days (range, 13-62 days). Two of the 54 patients had !6 months of follow-up (2 months and 5 months). Aortic valve replacements. There were 228 aortic valve replacements, and, regardless of the valve type being removed, an allograft was the favored replacement prosthesis in the majority of cases; it was used in 156 (68%) of 228 aortic valve replacements. No episode of relapse occurred after allograft replacement of an infected aortic valve, despite 45 (29%) of the allografts replacing culture-positive valves, 72 (46%) being inserted after invasive aortic annulus infection, and 25 (16%) both replacing culture-positive valves and being inserted after invasive aortic annulus infection.
Reducing treatment duration. Since 1994, we have suc-cessfully reduced the duration of treatment after surgery by ∼7 days for patients with culture-positive valves and by ∼14 days for those with culture-negative valves without an increase in relapse rate (table 5) .
DISCUSSION
The first valve replacement to treat active endocarditis was performed just over 40 years ago [25] . Despite concerns that such surgery would be followed by high relapse rates, 2 early reviews estimated the risk of relapse to be 1%-3% [20, 26] . Forty years later, we lack adequate data to guide the duration of antibiotic treatment after surgery. A major reason is that the literature has been written from a surgical perspective. Details of valve Gram stain results, culture results, and the duration of postoperative treatment are seldom contained within the same report. We therefore make a plea for authors to provide (and to reviewers and journal editors to request) a brief summary paragraph for all reports describing patients undergoing valve replacement for endocarditis. The paragraph should clearly state the number of patients undergoing operations before the end of the standard duration of antibiotic treatment, the number having completed standard treatment but still receiving antibiotics, the number with positive Gram stain and culture results, the number with infection extending beyond valve leaflets, the duration of postoperative antibiotic treatment, and the definitions of recurrence, treatment failure, and relapse. A brief history of each relapse should be provided so that readers can compare the case details for the patients experiencing relapse with those of the entire group being described. The interval between stopping antibiotic treatment and relapse should be stated. Ideally, isolates from the initial case of endocarditits and from the relapse should undergo molecular analysis to determine strain relatedness. There is also a need for clarity of meaning when referring to repeat episodes of endocarditis occurring after valve surgery. No fewer than 10 terms have been used, including "continu-ing," "persisting" or "persistent," "reacquired" [27] , "recurrent" (used by most authors), "reendocarditis" [28] , "reinfection" [20] , "relapse" or "relapsing" (used by many authors), "residual," "replacement valve endocarditis" [29] , and "second episode endocarditis." Different authors define the same word differently, and others, while acknowledging the difference between a relapse and a new infection, use the term "recurrent" to encompass both entities [30] . Clear definitions should be used by authors to convey the unambiguous meaning of what is being described.
Our study is the largest report describing bacteriological outcome after surgery for endocarditis. We observed that 9% of patients had a repeat episode of endocarditis after valve replacement surgery. This is in line with the median of 9% reported in the literature (range, 0%-23%) [6, 7, 10, 27, 28, . Our relapse rate of 0.8% is in line with the median of 1% reported in the literature (range, 0%-25%). There are 7 reports with no reported relapse, ranging in size from 8 to 90 patients [7, 39, 44, 46, 48, 54, 55] , 2 reports of 1% from studies involving 69 and 96 patients [10, 38] , and 5 reports of 6%-7% from studies involving 22-102 patients [6, 28, 36, 56, 57] . The 2 reports with the highest relapse rates (10% [58] and 25% [59] ) have only small patient numbers (19 and 4 patients, respectively).
Some have suggested that there should be no time limit for a subsequent episode to be defined as relapse [60] . We contend that a cutoff time is necessary and believe that 1 year is a conservative time period supported by several lines of evidence. First, in outbreaks of prosthetic valve endocarditis linked to contamination events at the time of surgery, the median incubation period was 2 months after surgery, with only 6% of 34 episodes presenting after 12 months [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] . Second, the interval between cessation of postoperative treatment and relapse was р3 months for 17 (81%) of 21 cases in which the interval has been stated by the authors, and all 21 patients with relapses presented within 6 months after stopping antibiotic treatment [6, 28, 36, 38, 59, 71] . Third, there is a well-described change in the relative proportion of causes of prosthetic valve endocarditis after 12 months [72] . On the basis of the literature and our own experience, most relapses can be expected to occur within 6 months after stopping antibiotic treatment.
Many reports and reviews have alluded to how culture or Gram stain results should influence the duration of therapy after surgery. Brambridge and Eykyn [73] suggest that, when an infected prosthetic valve is replaced, antibiotic therapy should be continued for 2 weeks if a culture of the valve is sterile but for 4-6 weeks if the causative organism is isolated from the valve. Most reports on surgery for endocarditis do not comment on the duration of antimicrobial therapy after valve replacement, and those that do so without commenting on why the duration was chosen [12] [13] [14] [15] [16] [17] [18] [19] [20] . Some reports mention that therapy should be longer for patients whose tissue has positive culture results [6, 7, [9] [10] [11] . Others have completed the planned course [74] or an individualized treatment duration determined on the basis of a number of factors [6, 8, 10, 20] . Others suggest a full course when the valve has a positive Gram stain result, even if the valve cultures are show no growth [5, 72] .
A recent exhaustive review of prosthetic valve endocarditis recommended that antibiotic therapy should be continued for at least 6 weeks after surgery [21] . A similar review, covering surgery for both native and prosthetic valve endocarditis, concluded that a minimum of 4-6 weeks of treatment should be completed after valve replacement for prosthetic valve endocarditis, regardless of the intraoperative culture results or length of preoperative antibiotic therapy [22] . For native valve endocarditis, the recommended duration of treatment after sur-gery varied from 7 days (when valve cultures were sterile and a full course of standard antimicrobial treatment had been completed) to 4-6 weeks (if the intraoperative cultures had positive results) [22] .
For patients with sterile valve cultures (of either native or prosthetic valves), we propose a different recommendation than a full course of antibiotic treatment on the basis of a positive microbiological or histopathological Gram stain finding. We do not consider that dead organisms pose an infection risk to the newly inserted valve prosthesis. We conclude, on the basis of the literature [6, 7, 9-11, 39, 73] and our experience reported here, that routinely treating patients with sterile valve cultures for 4-6 weeks after surgery is excessive. Over the past decade, we have successfully reduced the duration of antibiotic treatment for patients with negative results of valve cultures, irrespective of Gram stain or surgical findings, from 4 weeks to 2 weeks, without encountering relapse. Moreover, a further reduction in duration of treatment seems reasonable. For patients undergoing operations near the end of a commonly recommended duration of treatment [1, 2, 72] who have negative culture results and for whom there is no concern about metastatic infection, simply completing the planned course may be all that is required.
If any group of patients is at risk for relapse, it would most likely be those who have positive culture results at operation. Because of the significant morbidity and mortality associated with relapsing infection, we agree that it is prudent to restart the "antibiotic clock" from the day of surgery and to complete a recommended full course of treatment [1, 2, 72] . Nevertheless, the culture result needs to be considered alongside other factors (e.g., duration of treatment before surgery and the site of known or suspected extracardicac infection) when deciding on antimicrobial treatment duration after surgery.
Our study has several limitations. The data were retrospectively obtained from a single referral center that included complex cases referred from other New Zealand centers [54] . The observed relapse rate reflects the surgical intervention of a relatively small and experienced group of cardiothoracic surgeons. Their skill at debriding infected areas and reconstructing valvular and aortic outflow structures may have favorably influenced the outcome. It is important to note the common use of allograft valves as replacement devices in aortic valve endocarditis. We do not know what the relapse rate would have been if alternative prosthetic material and valves had been used, especially in extensive aortic root infection. Regrettably, we were unable to evaluate the molecular relatedness of isolates from initial cases of endocarditis and relapses. Molecular analysis is desirable if better-informed conclusions about the probability that repeat episodes represent therapy failure are to be made. Nevertheless, our study reports, to the best of our knowledge, the largest series of patients analyzed for bacteriological out-come after endocarditis, and we had follow-up information for all patients. Furthermore, only 3% of patients had !6 months of follow-up (the time period within which most relapses can be expected to occur).
In conclusion, we suggest that the duration of postoperative treatment for patients with negative valve culture results can be significantly shorter than the 4-6 weeks suggested by others. We provide preliminary evidence that 2 weeks of treatment is sufficient and suggest that even shorter courses are suitable for those undergoing operations late in the standard course of treatment for whom there is no concern about metastatic infection. The reduction in treatment duration will not only avoid unnecessary toxicity and health care costs but will also reduce the chance of intravenous line-associated bacteremia or fungamia and the risk that such events pose to newly inserted valve prostheses.
